Profit Maximization in the Pharmaceutical Sector

Profit Maximization in the Pharmaceutical Sector Kurt Kraetschmer explores the problem of profit maximization in the pharmaceutical sector and the possible prioritizing of profit above women's safety concerning birth control and contraception. The author suggests that health authorities who continue to propagate incorrect research and display ineptitude in matters about the safety of contraceptives should no longer get funds from taxpayers.

I partially agree with this position since health authorities must offer honest information regarding contraception and its possible hazards and advantages to the general population. But, I am also aware of the complicated forces in the pharmaceutical sector and the influence that commercial motivations may have on research and development.

Buy this excellently written paper or order a fresh one from ace-myhomework.com

The article presents examples of pharmaceutical corporations prioritizing profit above women's safety, such as marketing the contraceptive device Dalkon Shield in the 1970s despite recognized safety issues. Instead of depending on pharmaceutical firms to examine the safety of contraceptive techniques and convey correct information to the public, the author contends that health organizations should do so themselves.

In addition, the essay proposes that health authorities prioritize women's safety before profit maximization and spend funds appropriately. The author believes that government dollars should not be used to finance health authorities that propagate faulty research or display ineptitude about the safety of contraception.

However, it is essential to emphasize that funding considerations for health services are often complicated and multidimensional and may be based on something other than the agency's history of contraceptive safety. In addition, the pharmaceutical business is heavily controlled, and various protections are in place to guarantee that novel contraceptive techniques are carefully studied and authorized before being sold to the general population.

In conclusion, while I concur with the author's call for health agencies to prioritize women's safety in aspects of contraception and to disseminate accurate information, I am also aware of the complex factors at play in the pharmaceutical industry and the potential for profit incentives to impact research and development. Health authorities' funding selections should be carefully evaluated and based on various considerations, including their track record on contraceptive safety, but not primarily on this basis.